Inhibikase Therapeutics, Inc.IKTNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
26.38%
↓ 82% below average
Average (8y)
148.50%
Historical baseline
Range
High:1170.87%
Low:-64.99%
Volatility
832.2%
High variability
| Period | Value |
|---|---|
| 2024 | 26.38% |
| 2023 | 13.16% |
| 2022 | 5.95% |
| 2021 | 1170.87% |
| 2020 | -64.99% |
| 2019 | -30.01% |
| 2018 | 107.73% |
| 2017 | 107.43% |
| 2016 | 0.00% |